Abstract:Therapeutic Advances in Drug Safety, Volume 15, Issue , January-December 2024. Introduction:Clozapine, an antipsychotic used in the treatment of schizophrenia, is known for its serious side effects. In order to promote patient safety, drug–drug interaction (DDI) databases can be consulted by clinicians. In this study, the degree of consensus between five sources on DDIs with clozapine is determined.Methods:The summary of product characteristics of clozapine, Delphicare interaction database, Stockley's interaction checker, the Lexicomp interaction database, and the interaction database of Clinical Pharmacology are included. By comparing the original categories assigned to interactions with clozapine by the included DDI sources, a degree of consensus between sources is determined. Furthermore, based on the combined information, an evaluation on the severity of each potential interaction is made.Results:One hundred eighty-three potential DDIs with clozapine are retrieved from the five included sources. A consensus between sources is found in 47.5% (n = 87) of DDIs.Conclusion:This study shows major discrepancies between five different sources on DDIs with clozapine. The potential impact of the use of one specific database on patient safety and prescribing behavior could prove to be problematic.Plain language summaryA comparison of five sources on drug–drug interactions with clozapine: emphasizing the discrepancies between sources and determining the degree of severity of potential drug–drug interactionsClozapine is an antipsychotic agent advised to be used in the treatment of schizophrenia after two failed adequate treatments with other antipsychotics. A reluctance towards prescribing clozapine is described in literature, mainly because of its potential life threatening side effects. In assuring patient safety, evaluating potential interactions with other drugs are a key aspect in the risk assessment of clozapine. Drug–drug interaction (DDI) databases are developed to assist clinicians in this assessment.In this study we compare five sources on DDI with clozapine. Major discrepancies are found between sources with a consensus found in less than half of all included DDIs. It is hypothesized that these discrepancies can contribute to excessive caution or to negligence in prescribing clozapine. The impact of relying one specific database in the risk assessment of DDIs with clozapine could thus prove to be potentially problematic.Based on the comparison of the included sources, a conclusion was made on the severity of each unique potential DDI with clozapine. The results are shown in the appendix of supplementary materials.

Alert prescribing of clozapine: a comparison of five drug–drug interaction sources

Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis

Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 2016

Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature

Evaluation of major adverse events of clozapine based on accordance to an international titration guideline

A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness

Analysis of drug-drug interactions in spontaneous adverse drug reaction reports from EudraVigilance focusing on psychiatric drugs and somatic medication

Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data

Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients

Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland

The side effect profile of Clozapine in real world data of three large mental hospitals

Similarity and consistency assessment of three major online drug–drug interaction resources

Identification of serious drug-drug interactions: Results of the partnership to prevent drug-drug interactions

Exploring Off-Targets and Off-Systems for Adverse Drug Reactions Via Chemical-Protein Interactome--clozapine-induced Agranulocytosis As a Case Study.

Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database

Drug-drug interaction software in clinical practice: a systematic review

Interspecies variability and drug interactions of clozapine metabolism by microsomes

Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review

Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis

Assessing Consistency of Drug-Drug Interaction-Related Information Across Various Drug Information Resources